The Sluyser Archive: Science, History, and the Pursuit of Medical Truth

Welcome to the continuing work of the Sluyser Archive. Our editorial team maintains this independent science-and-history resource as a living repository for those who seek a deeper understanding of the intersections between biomedical research, regulatory policy, and public health outcomes. Named in honor of the Dutch pharmacologist and historian Dr. Mel Sluyser—whose pioneering studies on hormone receptors and drug safety set a standard for evidence-based inquiry—our site remains an active, daily-updated reference for scholars, journalists, healthcare professionals, and concerned citizens alike. We do not present ourselves as a relic of the past; rather, we are here, now, in 2026, curating and contextualizing the most pressing medical controversies of our time.

Our editorial philosophy is rooted in Sluyser’s own insistence on bridging laboratory science with historical perspective. He argued that no pharmaceutical safety crisis can be understood without tracing the full arc of discovery, clinical adoption, and eventual litigation. That principle guides every piece we publish. Whether we are examining the decades-long evolution of hormone therapy guidelines or the unforeseen carcinogenic pathways of widely prescribed drugs, we aim to give readers the scientific background, the regulatory chronology, and the legal frameworks that shape current debates. We are not a law firm, nor do we screen cases or match attorney referrals. We are an educational editorial operation—nothing more, and nothing less.

Reference Material and Historical Timelines

The heart of the Sluyser Archive lies in its detailed reference material. Our researchers compile structured timelines that trace the life cycle of major pharmaceutical agents: from early animal studies and clinical trials, through post-market surveillance, to the emergence of adverse-effect signals and their eventual adjudication in courts. Every entry is sourced from peer-reviewed journals, regulatory dockets, and court transcripts. For example, our coverage of the ranitidine (Zantac) contamination story—a case that exemplifies how an impurity (NDMA) can arise during manufacturing and storage—explains the chemistry, the FDA’s initial finding in 2019, the worldwide recall, and the subsequent wave of scientific studies investigating organ-specific cancer risks. For those seeking a detailed timeline of the litigation and its scientific basis, our dedicated guide on Zantac cancer lawsuit claims and legal information provides comprehensive reference material, including key study summaries and jurisdictional nuances. That resource is updated quarterly as new epidemiological research appears.

We also maintain curated bibliographies and data tables that allow readers to compare the NDMA content found in different batches of ranitidine with the levels considered acceptable by the U.S. Pharmacopeia. These are not raw dumps; they are annotated with editorial explanations that clarify the statistical assumptions, the thresholds used, and the limitations of each measurement method. Our goal is to make the science accessible without oversimplifying the uncertainty that always accompanies retrospective risk assessment.

Educational Scope and Audience

Who comes to the Sluyser Archive? Our readership spans several groups. First, there are academic and independent researchers who need a consolidated repository of historical data that they can cite in their own papers. Second, there are journalists covering ongoing product-liability litigation who require accurate medical context—understanding the difference between a relative risk increase and an attributable risk, for instance—so that their reporting does not mislead the public. Third, there are individuals affected by drug-related health issues who want to educate themselves about the scientific literature before consulting a physician or a lawyer. For them, we provide educational scope that covers basic concepts in pharmacokinetics, toxicology, and legal causation, all presented in plain language but with links to primary sources.

We also serve as a training ground for graduate students in public health and history of medicine. Our editorial team frequently commissions guest essays from doctoral candidates and early-career scientists, giving them a platform to present their findings in a format that bridges academic rigor and public readability. In that sense, the archive is not merely a collection—it is an active community of learners and contributors.

Looking ahead, we are expanding our scope to include emerging topics such as the environmental persistence of pharmaceutical residues and the long-term health effects of novel excipients. The Sluyser Archive will continue to adapt, but our core mission remains unchanged: to preserve the integrity of scientific discourse by providing clear, historically informed, and legally contextualized reference material. Browse our evolving catalog, and feel free to reach out to our editorial team with questions or suggestions. We are here, in real time, to help you navigate the tangled evidence.

Shifting focus to current realities, claimants should organize records, treatment chronology, and exposure evidence before legal intake. Compliance terms: FDA; statute of limitations; class action; MDL; mass tort; plaintiff; settlement; adverse event; litigation; compensation.